Aug 7, 2024 5:11 pm EDT Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.
Jul 30, 2024 8:00 am EDT Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
Jul 23, 2024 7:00 am EDT Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease
May 15, 2024 4:01 pm EDT Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
Apr 25, 2024 7:00 am EDT Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Apr 8, 2024 7:00 am EDT Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
Apr 3, 2024 7:00 am EDT Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
Mar 18, 2024 4:05 pm EDT Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update